Search results
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s):
Magdy Abdelhamid
,
Mostafa M Abdrabou
,
Emanuel Faris
,
et al
Added:
6 months ago
Review Article
Author(s):
Dominic Marcel Alfonso
Added:
2 months ago
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s):
Giovanni Battista Bonfioli
,
Matteo Pagnesi
,
Daniela Tomasoni
,
et al
Added:
8 months ago
Review Article
GLP-1RA in Different HFpEF Phenotypes
Author(s):
Aleksandra Bykova
,
Maria Serova
,
Maria Chashkina
,
et al
Added:
1 year ago
Review Article
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s):
Anastasia Shchendrygina
,
Amina Rakisheva
,
Ilya Giverts
,
et al
Added:
1 year ago
Review Article
The Role of GLP-1 in Heart Failure
Author(s):
Amina Rakisheva
,
Anton Zatsarinnyy
Added:
3 months ago
Editorial
Author(s):
Varun Sundaram
Added:
11 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
A Mark Richards
Research Area(s) / Expertise:
Job title: Director of the Christchurch Heart Institute
Author
Thomas Wolber
Job title: Electrophysiologist and Clinical Researcher
Author
